Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study

Ann Rheum Dis. 2012 Sep;71(9):1583-5. doi: 10.1136/annrheumdis-2011-201069. Epub 2012 May 5.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antirheumatic Agents / administration & dosage*
  • Arthritis, Rheumatoid / blood*
  • Arthritis, Rheumatoid / drug therapy*
  • Humans
  • Infliximab
  • Interleukin-6 / antagonists & inhibitors*
  • Interleukin-6 / blood
  • Methotrexate / administration & dosage
  • Remission Induction

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • IL6 protein, human
  • Interleukin-6
  • Infliximab
  • Methotrexate